68 related articles for article (PubMed ID: 23953881)
1. Suppression of SERPINA1-albumin complex formation by galectin-3 overexpression leads to paracrine growth promotion of chronic myelogenous leukemia cells.
Nakayama R; Kuroda J; Taniyama N; Yamamoto-Sugitani M; Wada S; Kiyota M; Mizutani S; Chinen Y; Matsumoto Y; Nagoshi H; Shimura Y; Kobayashi T; Horiike S; Sato K; Taniwaki M
Leuk Res; 2014 Jan; 38(1):103-8. PubMed ID: 23953881
[TBL] [Abstract][Full Text] [Related]
2. Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia.
Yamamoto-Sugitani M; Kuroda J; Ashihara E; Nagoshi H; Kobayashi T; Matsumoto Y; Sasaki N; Shimura Y; Kiyota M; Nakayama R; Akaji K; Taki T; Uoshima N; Kobayashi Y; Horiike S; Maekawa T; Taniwaki M
Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17468-73. PubMed ID: 21987825
[TBL] [Abstract][Full Text] [Related]
3. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
4. Effect of bone marrow mesenchymal stem cells from blastic phase chronic myelogenous leukemia on the growth and apoptosis of leukemia cells.
Han Y; Wang Y; Xu Z; Li J; Yang J; Li Y; Shang Y; Luo J
Oncol Rep; 2013 Aug; 30(2):1007-13. PubMed ID: 23733230
[TBL] [Abstract][Full Text] [Related]
5. Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia.
Kuroda J; Yamamoto M; Nagoshi H; Kobayashi T; Sasaki N; Shimura Y; Horiike S; Kimura S; Yamauchi A; Hirashima M; Taniwaki M
Mol Cancer Res; 2010 Jul; 8(7):994-1001. PubMed ID: 20571063
[TBL] [Abstract][Full Text] [Related]
6. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
Huang HM; Liu JC
J Cell Physiol; 2009 Mar; 218(3):568-74. PubMed ID: 19006173
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenesis effects of meisoindigo on chronic myelogenous leukemia in vitro.
Xiao Z; Wang Y; Lu L; Li Z; Peng Z; Han Z; Hao Y
Leuk Res; 2006 Jan; 30(1):54-9. PubMed ID: 15982734
[TBL] [Abstract][Full Text] [Related]
8. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
[TBL] [Abstract][Full Text] [Related]
9. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
10. In vitro effect of adenovirus-mediated human Gamma Interferon gene transfer into human mesenchymal stem cells for chronic myelogenous leukemia.
Li X; Lu Y; Huang W; Xu H; Chen X; Geng Q; Fan H; Tan Y; Xue G; Jiang X
Hematol Oncol; 2006 Sep; 24(3):151-8. PubMed ID: 16700092
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.
Li J; Xue L; Hao H; Han Y; Yang J; Luo J
Oncol Rep; 2012 Feb; 27(2):461-6. PubMed ID: 21993902
[TBL] [Abstract][Full Text] [Related]
12. Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity.
Xu R; Dong Q; Yu Y; Zhao X; Gan X; Wu D; Lu Q; Xu X; Yu XF
Leuk Res; 2006 Jan; 30(1):17-23. PubMed ID: 16023722
[TBL] [Abstract][Full Text] [Related]
13. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS
Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801
[TBL] [Abstract][Full Text] [Related]
15. Dup-697, a specific COX-2 inhibitor, suppresses growth and induces apoptosis on K562 leukemia cells by cell-cycle arrest and caspase-8 activation.
Peng HL; Zhang GS; Liu JH; Gong FJ; Li RJ
Ann Hematol; 2008 Feb; 87(2):121-9. PubMed ID: 17999062
[TBL] [Abstract][Full Text] [Related]
16. [Effects of ST1571 on the development of dendritic cells derived from bone marrow mononuclear cells in patients with chronic myeloid leukemia].
Zheng SE; Jin J; Tong XM; Qian WB; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):920-3. PubMed ID: 17533744
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
18. [Study of apoptosis induced by indomethacin in chronic myeloid leukemia].
Tu C; Zhang G; Lu H
Zhonghua Xue Ye Xue Za Zhi; 1999 Jul; 20(7):362-5. PubMed ID: 11721434
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow fibroblasts-conditioned medium regulates the proliferation of leukemic cells.
Kubota T; Nagao T; Arimori S
Tokai J Exp Clin Med; 1988 Feb; 13(1):45-51. PubMed ID: 3232161
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS
Mol Cancer Res; 2002 Dec; 1(2):89-95. PubMed ID: 12496355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
